Skip to main content
SpringerLink
Log in

Pharmacological Stone Prevention

  • Chapter
  • First Online:
Clinical Management of Urolithiasis

  • 1168 Accesses

Abstract

Pharmacological treatment is necessary in patients at high risk for recurrent stone formation. Mostly the medication is used in addition to general preventive measures. To achieve a reasonably good compliance, the ideal pharmacological agent should halt the formation of stones, be free of side effects and be easy to administer. The following chapter highlights briefly the most important characteristics of the commonly used substances and their stone specific application in recurrence prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Barbey F, Joly D, Rieu P, N’Guessau K, Daudon M, Jungers P (2000) Medical treatment of cystinuria: evaluation of long-term results in 30 patients. Presse Med 29(10):528–532

    PubMed  CAS  Google Scholar 

  • Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150(6):1761–1764

    PubMed  CAS  Google Scholar 

  • Birwe H, Schneeberger W, Hesse A (1991) Investigations of the efficacy of ascorbic acid therapy in cystinuria. Urol Res 19(3):199–201

    Article  PubMed  CAS  Google Scholar 

  • Borghi L, Meschi T, Guerra A, Novarini A (1993) Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 22(Suppl 6):S78–S86

    PubMed  Google Scholar 

  • Brocks P, Dahl C, Wolf H, Transbol I (1981) Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet 2(8238):124–125

    Article  PubMed  CAS  Google Scholar 

  • Cameron MA, Sakhaee K (2007) Uric acid nephrolithiasis. Urol Clin North Am 34(3):335–346

    Article  PubMed  Google Scholar 

  • Chow GK, Streem SB (1996) Medical treatment of cystinuria: results of contemporary clinical practice. J Urol 156(5):1576–1578

    Article  PubMed  CAS  Google Scholar 

  • Coe FL, Clark C, Parks JH, Asplin JR (2001) Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol 166(2):688–693

    Article  PubMed  CAS  Google Scholar 

  • Costanzo LS, Windhager EE (1978) Calcium and sodium transport by the distal convoluted tubule of the rat. Am J Physiol 235(5):F492–F506

    PubMed  CAS  Google Scholar 

  • Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ (1997) Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126(7):497–504

    PubMed  CAS  Google Scholar 

  • Denneberg T, Jeppsson JO, Stenberg P (1983) Alternative treat­­ment of cystinuria with alpha-merkaptopropionylglycine, Thiola. Proc Eur Dial Transplant Assoc 20:427–433

    PubMed  CAS  Google Scholar 

  • Dolin DJ, Asplin JR, Flagel L, Grasso M, Goldfarb DS (2005) Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. J Endourol 19(3):429–432

    Article  PubMed  Google Scholar 

  • Domrongkitchaiporn S, Khositseth S, Stitchantrakul W, Tapaneya-olarn W, Radinahamed P (2002) Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patients. Am J Kidney Dis 39(2):383–391

    Article  PubMed  CAS  Google Scholar 

  • Ettinger B, Tang A, Citron JT, Livermore B, Williams T (1986) Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 315(22):1386–1389

    Article  PubMed  CAS  Google Scholar 

  • Ettinger B, Citron JT, Livermore B, Dolman LI (1988) Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139(4):679–684

    PubMed  CAS  Google Scholar 

  • Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158(6):2069–2073

    Article  PubMed  CAS  Google Scholar 

  • Favus MJ, Coe FL (1980) The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. Scand J Urol Nephrol Suppl 53:265–271

    PubMed  CAS  Google Scholar 

  • Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR et al (2009) Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur Urol 56(1):72–80

    Article  PubMed  Google Scholar 

  • Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N (1991) Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol 20(3):243–247

    PubMed  CAS  Google Scholar 

  • Hesse A, Heimbach D (1999) Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 17(5):308–315

    Article  PubMed  CAS  Google Scholar 

  • Hesse AT, Tiselius H-G, Siener R, Hoppe B (eds) (2009) Urinary Stones, 3rd edn. Karger, Basel

    Google Scholar 

  • Hofbauer J, Hobarth K, Szabo N, Marberger M (1994) Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis–a prospective randomized study. Br J Urol 73(4):362–365

    Article  PubMed  CAS  Google Scholar 

  • Hoppe B, Kemper MJ (2010) Diagnostic examination of the child with urolithiasis or nephrocalcinosis. Pediatr Nephrol 25(3):403–413

    Article  PubMed  Google Scholar 

  • Hoppe B, Langman CB (2003) A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol 18(10):986–991

    Article  PubMed  Google Scholar 

  • Hoppe B, Beck BB, Milliner DS (2009) The primary hyperoxalurias. Kidney Int 75(12):1264–1271

    Article  PubMed  CAS  Google Scholar 

  • Jarrar K, Boedeker RH, Weidner W (1996) Struvite stones: long term follow up under metaphylaxis. Ann Urol (Paris) 30(3):112–117

    CAS  Google Scholar 

  • Johansson G, Backman U, Danielson BG, Fellstrom B, Ljunghall S, Wikstrom B (1982) Effects of magnesium hydroxide in renal stone disease. J Am Coll Nutr 1(2):179–185

    PubMed  CAS  Google Scholar 

  • Laerum E, Larsen S (1984) Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 215(4):383–389

    Article  PubMed  CAS  Google Scholar 

  • Maxwell AP (2007) Genetic renal abnormalities. Medicine 35(7):386–392

    Article  Google Scholar 

  • Miano L, Petta S, Galatioto GP et al (1985) A placebo controlled double-blind study of allopurinol in severe recurrent idiopathic renal lithiasis. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W (eds) Urolithiasis and related clinical research. Plenum Press, New York, pp 521–524

    Chapter  Google Scholar 

  • Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67(5):1704–1709

    Article  PubMed  CAS  Google Scholar 

  • Mortensen JT, Schultz A, Ostergaard AH (1986) Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. Int Urol Nephrol 18(3):265–269

    Article  PubMed  CAS  Google Scholar 

  • Ohkawa M, Tokunaga S, Nakashima T, Orito M, Hisazumi H (1992) Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol 69(6):571–576

    Article  PubMed  CAS  Google Scholar 

  • Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV (1986) Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 136(5):1003–1008

    PubMed  CAS  Google Scholar 

  • Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13(9):679–685

    Article  PubMed  CAS  Google Scholar 

  • Pearle MS, Asplin JR, Coe FL, Rodgers A, Worcester EM (2008) (Committee 3). Medical management of urolithiasis. In: Denstedt J, Khoury S (eds) 2nd International consultation on stone disease. Health Publications, Paris. pp 57–84. ISBN 0–9546956–7–4. http://www.icud.info/publications.html

  • Prien EL Sr, Gershoff SF (1974) Magnesium oxide-­pyridoxine therapy for recurrent calcium oxalate c­alculi. J Urol 112(4):509–512

    PubMed  Google Scholar 

  • Robertson WG, Peacock M, Selby PL et al (1985) Urolithiasis and related clinical research. Plenum Press, New York, pp 545–548

    Book  Google Scholar 

  • Schell-Feith EA, Moerdijk A, van Zwieten PH, Zonderland HM, Holscher HC, Kist-van Holthe J et al (2006) Does citrate prevent nephrocalcinosis in preterm neonates? Pediatr Nephrol 21(12):1830–1836

    Article  PubMed  Google Scholar 

  • Scholz D, Schwille PO, Sigel A (1982) Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 128(5):903–907

    PubMed  CAS  Google Scholar 

  • Silverberg SJ, Bilezikian JP (2006) The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab 2(9):494–503

    Article  PubMed  Google Scholar 

  • Sorensen HA (2002) Surgery for primary hyperparathyroidism. BMJ 325(7368):785–786

    Article  PubMed  Google Scholar 

  • Stitchantrakul W, Sopassathit W, Prapaipanich S, Domrongkitchaiporn S (2004) Effects of calcium supplements on the risk of renal stone formation in a population with low oxalate intake. Southeast Asian J Trop Med Public Health 35(4):1028–1033

    PubMed  CAS  Google Scholar 

  • Straub M, Strohmaier WL, Berg W, Beck B, Hoppe B, Laube N et al (2005) Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on stone disease for the upcoming German Urolithiasis guideline. World J Urol 23(5):309–323

    Article  PubMed  CAS  Google Scholar 

  • Takei K, Ito H, Masai M, Kotake T (1998) Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. Urol Int 61(3):192–195

    Article  PubMed  CAS  Google Scholar 

  • Tekin A, Tekgul S, Atsu N, Sahin A, Bakkaloglu M (2001) Cystine calculi in children: the results of a metabolic evaluation and response to medical therapy. J Urol 165(6 Pt 2):2328–2330

    PubMed  CAS  Google Scholar 

  • Tiselius HG, Berg C, Fornander AM, Nilsson MA (1993) Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microsc 7(1):381–389, discussion 9–90

    PubMed  CAS  Google Scholar 

  • Türk CKT, Petric A, Sarica K, Straub M, Seitz C (2011) Guidelines on Urolithiasis. In: Urology EAo (ed) EAU Guidelines, 2011th edn. EAU, Arnhem

    Google Scholar 

  • von Unruh GE, Voss S, Sauerbruch T, Hesse A (2004) Dependence of oxalate absorption on the daily calcium intake. J Am Soc Nephrol 15(6):1567–1573

    Article  Google Scholar 

  • Williams JJ, Rodman JS, Peterson CM (1984) A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. N Engl J Med 311(12):760–764

    Article  PubMed  CAS  Google Scholar 

  • Wilson DR, Strauss AL, Manuel MA (1984) Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. Urol Res 12:39–40

    Google Scholar 

  • Wong HY, Riedl CR, Griffith DP (1996) Medical management and prevention of struvite stones. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott-Raven, Philadelphia, pp 941–950

    Google Scholar 

  • Yendt ER (1970) Renal calculi. Can Med Assoc J 102(5):479–489

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Rechts der Isar Medical Center, Technische Universität München, Ismaninger Straße 22, D-81675, Munich, Germany

    Michael Straub M.D.

Authors
  1. Michael Straub M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Straub M.D. .

Editor information

Editors and Affiliations

  1. Klinik für Urologie, Klinikum Sindelfingen-Böblingen, Arthur-Gruber-Str. 70, Sindelfingen, 71065, Baden-Württemberg, Germany

    Thomas Knoll

  2. Center, Department of Urology, UT Southwestern Medical, 5323 Harry Hines, Blvd, Dallas, 75390, Texas, USA

    Margaret S. Pearle

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Straub, M. (2013). Pharmacological Stone Prevention. In: Knoll, T., Pearle, M. (eds) Clinical Management of Urolithiasis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28732-9_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-28732-9_20

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-28731-2

  • Online ISBN: 978-3-642-28732-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation